Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13
Benzinga Newsdesk 5 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Canaccord Genuity analyst John Newman upgrades Atara Biotherapeutics (NASDAQ:ATRA) from Hold to Buy and raises the price target from $6 to $13.
Canaccord Genuity analyst John Newman upgrades Atara Biotherapeutics (NASDAQ:ATRA) from Hold to Buy and raises the price target from $6 to $13.